loading...| Preferred Name | Prasterone | |
| Synonyms |
5,6-Dehydroisoandrosterone Dehydroisoandrosterone 17-Hormoforin Therapeutic Dehydroepiandrosterone Dehydroepiandrosterone dehydroepiandrosterone 3beta-Hydroxyandrost-5-en-17-one DHEA Diandron Fidelin GL701 PRASTERONE Prasterone |
|
| Definitions |
A synthetic form of dehydroepiandrosterone with potential chemopreventive activity. Produced endogenously, dehydroepiandrosterone (DHEA) is an intermediate in the conversion of cholesterol to androgens and estrogens. Although the mechanisms of action of exogenously administered DHEA have not been fully illuminated, they may result in both direct and indirect physiologic effects. Direct effects include GABA-a receptor complex and NMDA receptor modulation, and enhanced pancreatic beta cell insulin secretion and antiglucocorticoid activities. (NCI04) |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C2265 |
|
| Accepted_Therapeutic_Use_For |
Adrenal insufficiency, replacement; Systemic lupus erythematosus, treatment and steroid treatment reduction |
|
| ALT_DEFINITION |
A substance being studied in the prevention of cancer. It is a type of steroid. |
|
| CAS_Registry |
53-43-0 |
|
| CHEBI_ID |
CHEBI:28689 |
|
| Chemical_Formula |
C19H28O2 |
|
| code |
C2265 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142799 |
|
| Contributing_Source |
CTRP FDA |
|
| DEFINITION |
A synthetic form of dehydroepiandrosterone with potential chemopreventive activity. Produced endogenously, dehydroepiandrosterone (DHEA) is an intermediate in the conversion of cholesterol to androgens and estrogens. Although the mechanisms of action of exogenously administered DHEA have not been fully illuminated, they may result in both direct and indirect physiologic effects. Direct effects include GABA-a receptor complex and NMDA receptor modulation, and enhanced pancreatic beta cell insulin secretion and antiglucocorticoid activities. (NCI04) |
|
| Display_Name |
Prasterone |
|
| FDA_UNII_Code |
459AG36T1B |
|
| FULL_SYN |
5,6-Dehydroisoandrosterone Dehydroisoandrosterone 17-Hormoforin Therapeutic Dehydroepiandrosterone Dehydroepiandrosterone dehydroepiandrosterone 3beta-Hydroxyandrost-5-en-17-one DHEA Diandron Fidelin GL701 PRASTERONE Prasterone |
|
| Has_Salt_Form | ||
| label |
Prasterone |
|
| Legacy Concept Name |
Therapeutic_Dehydroepiandrosterone |
|
| NCI_Drug_Dictionary_ID |
42419 |
|
| NSC Number |
9896 |
|
| PDQ_Closed_Trial_Search_ID |
42419 |
|
| PDQ_Open_Trial_Search_ID |
42419 |
|
| Preferred_Name |
Prasterone |
|
| prefixIRI |
Thesaurus:C2265 |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C0011185 |
|
| subClassOf |